Validation of clinical tests used in physiotherapy diagnostics

Validation of clinical tests and diagnostic clusters in myofascial physiotherapy: a prospective clinical study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN14934633

Enrollment

120

Registered

2026-05-22

Start date

2026-05-29

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-specific neck pain, myofascial pain syndrome, shoulder pain and movement dysfunction, musculoskeletal disorders treated in physiotherapy Musculoskeletal Diseases

Interventions

The study is conducted as a prospective clinical research program including interventional and observational components in the field of myofascial physiotherapy. Adult participants with non-specific n

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Adults aged 18–60 years 2. Non-specific neck pain lasting from 1 month to 6 months 3. Presence of myofascial symptoms confirmed during physiotherapy examination 4. Pain intensity =4 on the Numeric Rating Scale (NRS) 5. Ability to participate in physiotherapy procedures and assessments 6. Signed informed consent

Exclusion criteria

Exclusion criteria: 1. Signs of serious spinal pathology (red flags) 2. Radiculopathy or neurological disorders 3. Previous spinal surgery within the last 12 months 4. Acute musculoskeletal injuries 5. Rheumatologic or systemic inflammatory diseases 6. Severe cardiovascular or systemic diseases 7. Recent interventional pain procedures 8. Pregnancy 9. Participation in another clinical trial within the last 3 months

Design outcomes

Secondary

Measure	Time frame
1. Cervical range of motion measured using an electronic or mechanical inclinometer in flexion, extension, lateral flexion, and rotation at baseline (T0), immediately after completion of therapy (T1), and 2 weeks after intervention completion (T3) 2. Biomechanical properties of myofascial tissues, including muscle tone, stiffness, and elasticity, measured using MyotonPRO at standardized points in the neck region at baseline (T0), immediately after completion of therapy (T1), and 2 weeks after intervention completion (T3) 3. Skin microcirculation measured using laser Doppler flowmetry with the PeriFlux System 5000 at standardized points in the neck region at baseline (T0), immediately after completion of therapy (T1), and 2 weeks after intervention completion (T3) 4. Global perceived change measured using the Global Rating of Change Scale (GROC) immediately after completion of therapy (T1) and 2 weeks after intervention completion (T3) 5. Patient satisfaction measured using a Patient Satisfaction Scale immediately after completion of therapy (T1) 6. Shoulder soft tissue and rotator cuff assessment measured using ultrasound examination with the SonoScape P20 ultrasound system in patients with suspected frozen shoulder during diagnostic assessment 7. Adherence to the intervention measured by attendance rate, completion of at least 80% of planned sessions, and duration of therapeutic sessions throughout the intervention period 8. Safety and tolerability measured by the number, type, severity, and timing of adverse events recorded throughout the study period	—

Measure

Time frame

1. Cervical range of motion measured using an electronic or mechanical inclinometer in flexion, extension, lateral flexion, and rotation at baseline (T0), immediately after completion of therapy (T1), and 2 weeks after intervention completion (T3) 2. Biomechanical properties of myofascial tissues, including muscle tone, stiffness, and elasticity, measured using MyotonPRO at standardized points in the neck region at baseline (T0), immediately after completion of therapy (T1), and 2 weeks after intervention completion (T3) 3. Skin microcirculation measured using laser Doppler flowmetry with the PeriFlux System 5000 at standardized points in the neck region at baseline (T0), immediately after completion of therapy (T1), and 2 weeks after intervention completion (T3) 4. Global perceived change measured using the Global Rating of Change Scale (GROC) immediately after completion of therapy (T1) and 2 weeks after intervention completion (T3) 5. Patient satisfaction measured using a Patient Satisfaction Scale immediately after completion of therapy (T1) 6. Shoulder soft tissue and rotator cuff assessment measured using ultrasound examination with the SonoScape P20 ultrasound system in patients with suspected frozen shoulder during diagnostic assessment 7. Adherence to the intervention measured by attendance rate, completion of at least 80% of planned sessions, and duration of therapeutic sessions throughout the intervention period 8. Safety and tolerability measured by the number, type, severity, and timing of adverse events recorded throughout the study period

—

Countries

Poland

Contacts

Public ContactRobert Trybulski

rtrybulski.provita@gmail.com+48 (0)502591428

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jun 11, 2026